Mineralys Therapeutics, Inc.
General ticker "MLYS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.6B (TTM average)
Mineralys Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -16.1%.
Estimated limits based on current volatility of 3.7%: low 28.07$, high 30.22$
Factors to consider:
- Total employees count: 76 (+49.0%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Limited operating history, Operational and conduct risks, Regulatory and compliance, Clinical trial failure, Insufficient capital
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [16.38$, 40.12$]
- 2026-12-31 to 2027-12-31 estimated range: [10.28$, 27.04$]
Financial Metrics affecting the MLYS estimates:
- Negative: with PPE of -15.6 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 97.72 > 81.92
- Negative: negative Industry operating income (median)
- Negative: negative Net income
- Negative: -0.37 < Inventory ratio change, % of 0
- Negative: Investing cash flow per share per price, % of -15.62 <= -11.23
Short-term MLYS quotes
Long-term MLYS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $84.66MM | $192.40MM | $170.60MM |
| Operating Income | $-84.66MM | $-192.40MM | $-170.60MM |
| Non-Operating Income | $12.76MM | $14.59MM | $15.95MM |
| R&D Expense | $70.36MM | $168.58MM | $132.01MM |
| Income(Loss) | $-71.90MM | $-177.81MM | $-154.65MM |
| Net Income(Loss)* | $-71.90MM | $-177.81MM | $-154.65MM |
| Stockholders Equity | $241.15MM | $191.26MM | $646.69MM |
| Assets | $251.64MM | $205.90MM | $661.81MM |
| Operating Cash Flow | $-81.17MM | $-166.31MM | $-142.42MM |
| Capital expenditure | $0.00MM | $0.10MM | $0.01MM |
| Investing Cash Flow | $-160.47MM | $114.96MM | $-389.75MM |
| Financing Cash Flow | $203.25MM | $116.14MM | $591.00MM |
| Earnings Per Share** | $-1.99 | $-3.66 | $-2.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.